SCHEMBL32665352

SCHEMBL32665352

COC(=O)C1CCN(c2ccc3nnc(-c4ccc(Cl)cc4)n3n2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.57
ALDH1A1 P00352 7/20 0.57
HPGD P15428 7/20 0.57
KDM4E B2RXH2 6/20 0.57
HTT P42858 3/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
TSHR P16473 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
TP53 P04637 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
HSD17B10 Q99714 5/20 0.52
LMNA P02545 2/20 0.51
POLB P06746 2/20 0.49
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
PIM1 P11309 2/20 0.47
DPP4 P27487 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32664943 0.92 ALDH1A1 (0.53) MAPTALDH1A1HPGDKDM4EHTT
SCHEMBL32664969 0.90 HSD17B10 (0.63) MAPTALDH1A1HPGDKDM4EHTT
SCHEMBL32665526 0.90 MAPT (0.57) MAPTALDH1A1HPGDKDM4EHTT
SCHEMBL32665179 0.89 HPGD (0.54) MAPTALDH1A1HPGDKDM4EHTT
SCHEMBL32665051 0.89 MEN1 (0.53) MAPTALDH1A1HPGDKDM4EHTT
SCHEMBL32665102 0.88 DPP4 (0.56) MAPTALDH1A1HPGDKDM4EHTT
SCHEMBL32664891 0.87 KDM4E (0.53) MAPTALDH1A1HPGDKDM4EHTT
SCHEMBL32665398 0.85 ALDH1A1 (0.48) MAPTALDH1A1HPGDKDM4EHTT
SCHEMBL32664995 0.84 DPP4 (0.67) MAPTALDH1A1HPGDKDM4EHTT
SCHEMBL32664897 0.82 DPP4 (0.59) MAPTALDH1A1HPGDKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022124-A1 THERAPEUTIC COMPOUNDS AND METHODS UNIV MINNESOTA (US) 2026-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022124-A1 THERAPEUTIC COMPOUNDS AND METHODS NR5A1, CYP17A1, CNR1 MAPT 4516/4885ALDH1A1 663/4885HPGD 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.